BACKGROUND: High-potency statins reduce @entity65 after @entity1187 but remain underused in clinical practice. We examined predictors of nonuse of high-potency statins after @entity1187 . METHODS AND RESULTS: The Stabilization of pLaques usIng Darapladib-Thrombolysis in @entity583 (SOLID-TIMI 52) trial enrolled @entity1 after an @entity1187 in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician. A high-potency statin was defined as >= 40  mg @entity2993 , >= 20  mg @entity8671 , or 80  mg @entity3413 daily. Predictors of nonuse of high-potency statins were examined using logistic regression. Of the @entity1 included (n=12  446), 11  850 (95.2%) were treated with a statin at baseline after @entity1187 (median 14  days), but only 5212 (41.9%) were on a high-potency statin. Selected @entity1 factors associated with nonuse of high-potency statins included age >= 75  years (odds ratio 1.39, 95% CI 1.24-1.56), female sex (odds ratio 1.11, 95% CI 1.02-1.22), @entity8 (odds ratio 1.17, 95% CI 1.03-1.32), and @entity712 during hospital admission (odds ratio 1.43, 95% CI 1.27-1.62). At 3  months after baseline, only 49% of @entity1 had low-density lipoprotein @entity165 <70  mg/dL. Among the 5490 @entity1 (59%) who were not on a high-potency statin at 3  months, lower low-density lipoprotein @entity165 was a predictor of nonuse of a high-potency statin after a median of 2.3  years (odds ratio 1.15 for 10  mg/dL decrease, 95% CI 1.11-1.19). CONCLUSION: Despite the widespread use of statins after @entity1187 , most @entity1 are not treated with high-potency statins early and late after the event, including @entity1 at the highest risk of recurrent @entity65 . CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01000727.

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in XXXX 52 (SOLID-TIMI 52) Trial.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndrome', 'acute coronary syndromes'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity3413 :: ('MESH:D019821', 'Chemical') :: ['simvastatin'] @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin'] @entity8671 :: ('MESH:C422923', 'Chemical') :: ['rosuvastatin'] @entity583 :: ('MESH:D009203', 'Disease') :: ['Myocardial Infarction'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular events'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity583 :: (MESH:D009203,Disease) :: ['Myocardial Infarction']
